CDMO:NSD-Avid Bioservices, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.50

Change

+0.72 (+8.20)%

Market Cap

USD 0.50B

Volume

0.83M

Average Target Price

USD 12.00 (+26.32%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.60 (-1.56%)

USD59.89B 22.57 17.39
MRNA Moderna, Inc

+1.99 (+1.41%)

USD55.80B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

-8.94 (-1.74%)

USD54.85B 18.84 14.53
SGEN Seagen Inc

-0.37 (-0.21%)

USD31.76B 67.00 62.62
BNTX BioNTech SE

+7.08 (+6.21%)

USD29.92B -99,999.99 N/A
RPRX Royalty Pharma plc

-1.00 (-2.34%)

USD26.75B 22.60 9.74
ALXN Alexion Pharmaceuticals, Inc

+0.60 (+0.49%)

USD26.73B 28.35 26.92
GMAB Genmab A/S

+0.08 (+0.21%)

USD25.29B 26.59 2.61
BGNE BeiGene, Ltd

-19.49 (-7.91%)

USD24.48B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CDMO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.86% 62% D- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.86% 62% D- 70% C-
Trailing 12 Months  
Capital Gain 64.93% 70% C- 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.93% 70% C- 82% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.05% N/A N/A 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.05% N/A N/A 74% C
Risk Return Profile  
Volatility (Standard Deviation) 25.77% N/A N/A 57% F
Risk Adjusted Return 66.16% N/A N/A 81% B-
Market Capitalization 0.50B 62% D- 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.87 16% F 12% F
Price / Cash Flow Ratio 85.29 1% F 4% F
EV/EBITDA 712.25 3% F 2% F
Management Effectiveness  
Return on Equity -5.35% 92% A- 46% F
Return on Invested Capital -22.02% 83% B 28% F
Return on Assets -1.50% 93% A 40% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.96 35% F 21% F
Short Percent 3.58% 69% D+ 47% F
Beta 2.34 14% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.